SG11202001930QA - Proteins binding nkg2d, cd16 and a tumor-associated antigen - Google Patents
Proteins binding nkg2d, cd16 and a tumor-associated antigenInfo
- Publication number
- SG11202001930QA SG11202001930QA SG11202001930QA SG11202001930QA SG11202001930QA SG 11202001930Q A SG11202001930Q A SG 11202001930QA SG 11202001930Q A SG11202001930Q A SG 11202001930QA SG 11202001930Q A SG11202001930Q A SG 11202001930QA SG 11202001930Q A SG11202001930Q A SG 11202001930QA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor
- associated antigen
- proteins binding
- binding nkg2d
- nkg2d
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762555110P | 2017-09-07 | 2017-09-07 | |
US201762566824P | 2017-10-02 | 2017-10-02 | |
PCT/US2018/050073 WO2019051308A1 (en) | 2017-09-07 | 2018-09-07 | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001930QA true SG11202001930QA (en) | 2020-04-29 |
Family
ID=65634405
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202102502VA SG10202102502VA (en) | 2017-09-07 | 2018-09-07 | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
SG11202001930QA SG11202001930QA (en) | 2017-09-07 | 2018-09-07 | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202102502VA SG10202102502VA (en) | 2017-09-07 | 2018-09-07 | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
Country Status (13)
Country | Link |
---|---|
US (3) | US20200277383A1 (en) |
EP (2) | EP3925976A1 (en) |
JP (3) | JP7431392B2 (en) |
KR (2) | KR20200044957A (en) |
CN (2) | CN113004417A (en) |
AU (2) | AU2018329937A1 (en) |
BR (1) | BR112020004489A2 (en) |
CA (2) | CA3112984A1 (en) |
IL (2) | IL273067A (en) |
MX (2) | MX2020002626A (en) |
RU (1) | RU2021110369A (en) |
SG (2) | SG10202102502VA (en) |
WO (1) | WO2019051308A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3221995A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
PE20210375A1 (en) * | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | CANCER COMBINATION THERAPY INCLUDING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS |
MX2020008336A (en) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor. |
EP3870598A1 (en) | 2018-10-23 | 2021-09-01 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
WO2021087245A1 (en) * | 2019-10-30 | 2021-05-06 | The Texas A&M University System | Protease switch for dual targets chimeric antigen receptor t cell therapy |
US20230272041A1 (en) * | 2020-04-22 | 2023-08-31 | Dragonfly Therapeutics, Inc. | Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins |
MX2023003059A (en) * | 2020-09-17 | 2023-06-02 | Agensys Inc | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins. |
CN113563474B (en) * | 2021-06-11 | 2023-05-02 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | EpCAM-CD16-NKG2D trispecific antibody and application thereof |
WO2023023659A1 (en) * | 2021-08-20 | 2023-02-23 | Tallac Therapeutics, Inc. | Nectin-4 antibodies and conjugates |
AR127162A1 (en) * | 2021-09-29 | 2023-12-27 | Dragonfly Therapeutics Inc | PROTEINS THAT BIND NKG2D, CD16 AND BAFF-R |
KR20230060546A (en) * | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | ANTIGEN BINDING PROTEINS WITH TWO Fc DOMAINS AND USE THEREOF |
WO2024026253A1 (en) * | 2022-07-25 | 2024-02-01 | Agensys, Inc. | Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003111595A (en) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | Tumor antigen |
CN1812999A (en) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | Pharmaceutical composition comprising a bispecific antibody specific for EpCAM |
EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
US8383118B2 (en) | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
WO2010067487A1 (en) * | 2008-12-12 | 2010-06-17 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
CA2754531A1 (en) | 2009-03-06 | 2010-09-30 | Seattle Genetics, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
JP5758888B2 (en) * | 2009-07-06 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific digoxigenin binding antibody |
KR102295534B1 (en) * | 2010-09-29 | 2021-08-30 | 어젠시스 인코포레이티드 | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
EP2710042A2 (en) * | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
JP6571527B2 (en) * | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
CA2900764A1 (en) * | 2013-02-08 | 2014-08-14 | Stemcentrx, Inc. | Novel multispecific constructs |
KR20160030936A (en) * | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
EP3327038B1 (en) * | 2013-12-20 | 2020-09-23 | F. Hoffmann-La Roche AG | Bispecific her2 antibodies and methods of use |
BR112016014913A8 (en) * | 2013-12-23 | 2020-06-09 | Zymeworks Inc | antibody, or an antigen-binding fragment thereof, conjugate, nucleic acid, vector, host cell, pharmaceutical composition, method of preparing an antibody light chain or antigen-binding fragment, and method of preparing a conjugate |
US20180318417A1 (en) * | 2015-01-14 | 2018-11-08 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
CN107530424A (en) | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | For NKG2D and the bivalent antibody of tumor associated antigen |
US10675357B2 (en) * | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
-
2018
- 2018-09-07 JP JP2020513796A patent/JP7431392B2/en active Active
- 2018-09-07 CA CA3112984A patent/CA3112984A1/en active Pending
- 2018-09-07 EP EP21164073.5A patent/EP3925976A1/en not_active Withdrawn
- 2018-09-07 MX MX2020002626A patent/MX2020002626A/en unknown
- 2018-09-07 RU RU2021110369A patent/RU2021110369A/en unknown
- 2018-09-07 WO PCT/US2018/050073 patent/WO2019051308A1/en active Application Filing
- 2018-09-07 CN CN202110251101.6A patent/CN113004417A/en active Pending
- 2018-09-07 KR KR1020207009780A patent/KR20200044957A/en not_active Application Discontinuation
- 2018-09-07 EP EP18853095.0A patent/EP3679071A4/en active Pending
- 2018-09-07 KR KR1020217007213A patent/KR20210030503A/en not_active Application Discontinuation
- 2018-09-07 CA CA3074840A patent/CA3074840A1/en active Pending
- 2018-09-07 AU AU2018329937A patent/AU2018329937A1/en active Pending
- 2018-09-07 SG SG10202102502VA patent/SG10202102502VA/en unknown
- 2018-09-07 US US16/644,585 patent/US20200277383A1/en not_active Abandoned
- 2018-09-07 CN CN201880071464.8A patent/CN111315782A/en active Pending
- 2018-09-07 SG SG11202001930QA patent/SG11202001930QA/en unknown
- 2018-09-07 BR BR112020004489-0A patent/BR112020004489A2/en unknown
-
2020
- 2020-03-04 IL IL273067A patent/IL273067A/en unknown
- 2020-03-06 MX MX2021002970A patent/MX2021002970A/en unknown
-
2021
- 2021-03-02 US US17/190,155 patent/US20210292420A1/en not_active Abandoned
- 2021-03-08 IL IL281323A patent/IL281323A/en unknown
- 2021-03-09 AU AU2021201494A patent/AU2021201494A1/en active Pending
- 2021-03-09 JP JP2021037490A patent/JP2021098733A/en active Pending
-
2023
- 2023-02-13 US US18/108,961 patent/US20230357409A1/en active Pending
- 2023-08-14 JP JP2023132099A patent/JP2023166409A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG10202102502VA (en) | 2021-04-29 |
BR112020004489A2 (en) | 2020-09-08 |
CN113004417A (en) | 2021-06-22 |
IL273067A (en) | 2020-04-30 |
RU2021110369A (en) | 2021-06-01 |
AU2021201494A1 (en) | 2021-03-25 |
KR20210030503A (en) | 2021-03-17 |
AU2018329937A1 (en) | 2020-03-19 |
JP7431392B2 (en) | 2024-02-15 |
US20230357409A1 (en) | 2023-11-09 |
RU2020112333A (en) | 2021-10-08 |
JP2023166409A (en) | 2023-11-21 |
JP2020533311A (en) | 2020-11-19 |
EP3679071A1 (en) | 2020-07-15 |
US20210292420A1 (en) | 2021-09-23 |
CA3074840A1 (en) | 2019-03-14 |
CA3112984A1 (en) | 2019-03-14 |
MX2020002626A (en) | 2020-10-07 |
IL281323A (en) | 2021-04-29 |
WO2019051308A1 (en) | 2019-03-14 |
CN111315782A (en) | 2020-06-19 |
US20200277383A1 (en) | 2020-09-03 |
MX2021002970A (en) | 2021-05-12 |
EP3679071A4 (en) | 2021-06-09 |
JP2021098733A (en) | 2021-07-01 |
EP3925976A1 (en) | 2021-12-22 |
KR20200044957A (en) | 2020-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280673A (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
IL281323A (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
IL270803A (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
IL268755A (en) | Proteins binding her2, nkg2d and cd16 | |
IL272706A (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
IL270801A (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
MX2020000960A (en) | Anti-tigit antibodies. | |
IL270794A (en) | A protein binding nkg2d, cd16 and ror1 or ror2 | |
IL268567A (en) | Proteins binding bcma, nkg2d and cd16 | |
IL281305A (en) | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 | |
ZA202003641B (en) | Antibodies binding ctla-4 and uses thereof | |
IL268790A (en) | Proteins binding cd33, nkg2d and cd16 | |
IL280618A (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
IL268574A (en) | Proteins binding psma, nkg2d and cd16 | |
IL280656A (en) | Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use | |
IL268766A (en) | Proteins binding cd123, nkg2d and cd16 | |
IL268768A (en) | Proteins binding gd2, nkg2d and cd16 | |
IL272374A (en) | Proteins binding nkg2d, cd16 and flt3 | |
SG11202011139YA (en) | Protein binding nkg2d, cd16 and a fibroblast activation protein | |
EP3790585A4 (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
ZA201905273B (en) | Proteins binding psma, nkg2d and cd16 | |
CA3235295A1 (en) | Proteins binding her2, nkg2d and cd16 |